Company intelligence / Profile preview

AquaBounty Technologies

Harvard, Massachusetts, United Statesinvestors.aquabounty.com ↗

Ownership: Private
Employees: ~4
Development stage: Other

Overview

AquaBounty developed the first FDA-approved genetically engineered animal for human consumption—AquAdvantage Salmon—which grows to market size faster than conventional Atlantic salmon. The product was approved by regulators in the US and Canada. The company operated land-based RAS farms but faced financial difficulties leading to operational wind-down at its last active site by end of 2024.

Therapeutic areas: Other
Modalities: Genetically engineered organism (GMO)Recombinant protein technology
Industry: Non-Drug Biotech

Partnerships

Collaborations with research institutions/universities/regulatory bodiespartnerships with fish farmers/aquaculture companies to scale operations.

Beyond the preview

Go deeper on AquaBounty Technologies.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AquaBounty Technologies.

Explore the full profile